Proteomics

Dataset Information

0

Inhibition of osteosarcoma progression by sporoderm-removed ganoderma lucidum spores


ABSTRACT: Osteosarcoma (OS) is a severe malignancy affecting children and adolescents, with limited effective treatments leading to poor outcomes. This study explored the potential of sporoderm-removed Ganoderma lucidum spores (RGLS) as a novel therapeutic agent against OS and elucidated its mechanism of action. Our in vivo and in vitro experiments showed that RGLS significantly inhibited S-180 OS cell proliferation, colony formation, and migration, while simultaneously inducing apoptosis. Multi-omics analysis revealed that RGLS disrupted glycerophospholipid metabolism by upregulating lysophosphatidylcholine (LysoPC) levels through phospholipase A2 (PLA2)-mediated pathways. Co-culture assays further demonstrated that RGLS promoted the endocytosis of macrophage-derived Pla2g7 protein into S-180 cells, enhancing its anti-cancer effects. Additionally, RGLS modulated the cellular fatty acid profile and suppressed the β-oxidation of long-chain fatty acids, leading to energy depletion in OS cells. These findings provide a novel view of the multi-targeted mechanisms of RGLS, positioning it as a promising candidate for OS therapy.

ORGANISM(S): Mus Musculus

SUBMITTER: Jihong Yang  

PROVIDER: PXD056264 | iProX | Wed Sep 25 00:00:00 BST 2024

REPOSITORIES: iProX

Similar Datasets

2021-08-24 | GSE176373 | GEO
2021-07-19 | GSE172295 | GEO
2008-06-18 | E-GEOD-7077 | biostudies-arrayexpress
2007-12-31 | GSE7077 | GEO
2022-06-07 | GSE205188 | GEO
2023-03-01 | GSE225588 | GEO
2016-08-26 | GSE86053 | GEO
2012-09-01 | E-GEOD-30934 | biostudies-arrayexpress
2024-06-28 | GSE262743 | GEO
2008-06-16 | E-GEOD-9654 | biostudies-arrayexpress